Biphasic Behavior of Anti-M Antibody and Hemolytic Disease of the Fetus and Newborn (HDFN).

The anti-M antibody is a cold, naturally occurring immunoglobulin M (IgM) antibody that is generally considered clinically insignificant and often overlooked in transfusion practices and assessments of patients at risk for hemolytic disease of the fetus and newborn (HDFN). However, the presence of an IgG component in this case renders the antibody clinically significant, underscoring the necessity for proper serologic testing during prenatal evaluations. We present a case involving an anti-M antibody with an IgG component to highlight the critical importance of thorough serologic testing during prenatal testing.

Breast Cancer Recurrence in Initially Clinically Node-Positive Patients Undergoing Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in the NEOSENTITURK-Trials MF18-02/18-03.

Background: This study aims to identify factors predicting recurrence and unfavorable prognosis in cN+ patients who have undergone sentinel lymph node biopsy (SLNB) following neoadjuvant chemotherapy (NAC).

Methods: The retrospective multi-centre "MF18-02" and the prospective multi-centre cohort registry trial "MF18-03" (NCT04250129) included patients with cT1-4N1-3M0 with SLNB+/- axillary lymph node dissection (ALND) post-NAC.

Results: A total of 2407 cN+ patients, who later achieved cN0 status after NAC and subsequently underwent SLNB, were studied.

Multi-responsive shape memory and self-healing hydrogels with gold and silver nanoparticles.

Nanocomposite smart gels (Nc-) with self-healing and shape memory properties were designed in different types and size nano particles with temperature or light stimuli. Nc- networks were prepared by bulk polymerization of stearyl methacrylate (SM) and vinyl pyrrolidone (VP) in the presence of gold and silver nanoparticles. The structure, which does not contain any chemical cross-linkers, is held together by hydrophobic interactions while consisting of dipole-dipole bonds of the VP units and long alkyl groups in the side chains of the SM.

Correction of Griscelli Syndrome Type 2 causing mutations in the gene with CRISPR/Cas9.

Background/aim: Griscelli Syndrome Type 2 (GS-2) is a rare, inherited immune deficiency caused by a mutation in the gene. The current treatment consists of hematopoietic stem cell transplantation, but a lack of suitable donors warrants the development of alternative treatment strategies, including gene therapy. The development of mutation-specific clustered regularly interspaced palindromic repeats (CRISPR)/Cas9 gene editing technology has opened the way for custom-designed gene correction of patient-derived stem cells.